Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 7, 2009; 15(29): 3636-3642
Published online Aug 7, 2009. doi: 10.3748/wjg.15.3636
Published online Aug 7, 2009. doi: 10.3748/wjg.15.3636
Table 1 Baseline patient characteristics n (%)
| Imipramine (n = 59) | Placebo (n = 48) | |
| Mean age (yr) | 42.6 ± 12.4 | 45.3 ± 13.8 |
| Male sex | 33 (55.9) | 29 (60.4) |
| Type of recruitment | 38 (64.4) referrals | 29 (60.4) referrals |
| Bloating/distention | 57 (96.6) | 46 (95.8) |
| Abdominal pain | 58 (98.3) | 47 (97.9) |
| Flatulence | 45 (76.3) | 40 (83.3) |
| Constipation | 17 (28.8) | 15 (31.3) |
| Diarrhea | 11 (18.6) | 7 (14.6) |
| Mixed pattern | 14 (23.7) | 15 (31.3) |
| Mean baseline SF-36 score | 98.6 ± 21.3 | 102.8 ± 16.6 |
- Citation: Abdul-Baki H, El Hajj II, ElZahabi L, Azar C, Aoun E, Skoury A, Chaar H, Sharara AI. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol 2009; 15(29): 3636-3642
- URL: https://www.wjgnet.com/1007-9327/full/v15/i29/3636.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3636